Telix制药公司在前列腺癌成像药物Illuccix的驱动下, Q4收入猛增46%至142M。 Telix Pharmaceuticals saw Q4 revenue soar 46% to $142M, driven by prostate cancer imaging drug Illuccix.

Telix制药公司报告,4 2024Q4收入增加46%,达到1.42亿美元,超过了2024财政年度收入指导,达到5.17亿美元。 Telix Pharmaceuticals reported a 46% jump in Q4 2024 revenue to $142 million, surpassing its FY2024 revenue guidance to reach $517 million. 增长主要归因于Illuccix的销售,Illuccix是前列腺癌症PET成像的诊断性放射药物。 The growth is mainly attributed to sales of Illuccix, a diagnostic radiopharmaceutical for prostate cancer PET imaging. 该公司还推进了其治疗资产,并从ImaginAb公司购买了一个药物发现平台。 Telix公司计划在2025年2月20日提供FY2025指导。 The company also advanced its therapeutic assets and acquired a drug discovery platform from ImaginAb Inc. Telix plans to provide FY2025 guidance on February 20, 2025.